Overall Survival

Treatment with JAKAVI offers your MF patients extended survival benefit¹

Myelofibrosis Is Associated With Reduced survival by 40% at 5 years, 60% at 10 years²

Extend your MF patients’ survival with JAKAVI at diagnosis³

Timing matters: Treat at diagnosis

OS: Overall survival

For JAKAVI-MF Abbreviated prescribing information

PDF

References

Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, The Journal of the American Society of Hematology. 2009 Mar 26;113(13):2895-901
Verstovsek S, Gupta V, Gotlib JR, et al. A pooled overall survival (OS) analysis of 5-year data fr om the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF). Blood. 2016;128(22):3110.
Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P. Long-term survival in patients
treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. Journal of hematology & oncology. 2017 Dec;10:1-6

Approved by Egyptian Drug Authority: HF0424OA4703/102025. Invalidation date: 17/12/2025.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.